ISIN | CH0594527720 |
---|---|
Valor Number | 59452772 |
Bloomberg Global ID | UBPAIIX SW |
Fund Name | UBS (CH) Investment Fund - Equities Switzerland ESG Passive All II I-X |
Fund Provider |
UBS Asset Management Switzerland AG, Zurich
Basel, Switzerland Phone: +41 61 288 75 01 E-Mail: sh-ubs-funds-feedback@ubs.com Web: www.ubs.com/fonds |
Fund Provider | UBS Asset Management Switzerland AG, Zurich |
Representative in Switzerland | |
Distributor(s) |
UBS AG Basel Phone: +41 61 288 20 20 |
Asset Class | Bonds |
EFC Category | Equity Switzerland |
Distribution Policy | Accumulation |
Home Country | Switzerland |
Issuing Condition | The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | Das Anlageziel dieses Teilvermögens besteht hauptsächlich darin, den repräsentativen Referenzindex SPI® ESG (TR) für den schweizerischen Aktienmarkt (Bench-mark) passiv nachzubilden und eine Performance zu erzielen, welche dessen Entwicklung entspricht. |
Peculiarities |
Current Price * | 1,138.35 CHF | 14.11.2024 |
---|---|---|
Previous Price * | 1,131.24 CHF | 13.11.2024 |
52 Week High * | 1,199.81 CHF | 02.09.2024 |
52 Week Low * | 1,020.72 CHF | 16.11.2023 |
NAV * | 1,138.35 CHF | 14.11.2024 |
Issue Price * | 1,138.35 CHF | 14.11.2024 |
Redemption Price * | 1,138.35 CHF | 14.11.2024 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 2,114,229,593 | |
Unit/Share Assets *** | 1,732,539,457 | |
Trading Information SIX |
YTD Performance | +7.25% |
29.12.2023 - 14.11.2024
29.12.2023 14.11.2024 |
---|---|---|
1 month | -4.05% |
14.10.2024 - 14.11.2024
14.10.2024 14.11.2024 |
3 months | -2.37% |
14.08.2024 - 14.11.2024
14.08.2024 14.11.2024 |
6 months | -0.54% |
14.05.2024 - 14.11.2024
14.05.2024 14.11.2024 |
1 year | +10.86% |
14.11.2023 - 14.11.2024
14.11.2023 14.11.2024 |
2 years | +11.58% |
14.11.2022 - 14.11.2024
14.11.2022 14.11.2024 |
3 years | -1.33% |
15.11.2021 - 14.11.2024
15.11.2021 14.11.2024 |
5 years | +18.09% |
11.02.2021 - 14.11.2024
11.02.2021 14.11.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Nestle SA | 13.86% | |
---|---|---|
Novartis AG Registered Shares | 12.44% | |
Roche Holding AG | 12.21% | |
UBS Group AG | 5.56% | |
ABB Ltd | 4.96% | |
Zurich Insurance Group AG | 4.85% | |
Compagnie Financiere Richemont SA Class A | 4.37% | |
Holcim Ltd | 2.99% | |
Alcon Inc | 2.58% | |
Sika AG | 2.50% | |
Last data update | 31.10.2024 |
TER | 0.01% |
---|---|
TER date | 30.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | |
Ongoing Charges *** | 0.00% |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |
GMOs |